HEIMDALL-POWER
Heimdall Power, the global leader in power grid optimization, today announced a $25 million USD capital raise in a Series B financing. The round was co-led by the international energy company Orlen, Nordic cleantech fund NRP Zero, and the Steinsvik Family Office. Existing shareholders, including Investinor, Eviny, Hafslund, Lyse, and Sarsia Seed, participated in the round with a combined $8.5 million USD.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716656922/en/
New and existing investors united in Heimdall Power’s Oslo HQ to celebrate the successful funding round. Photo: Jola McDonald
Founded in 2016, Heimdall Power delivers software and sensors for the monitoring of overhead power lines. The technology enables electric utilities to increase transmission capacity in their high-voltage power grids by 40% on average, while simultaneously improving the safety and efficiency of their operations. Heimdall Power’s solutions allow utilities to optimize existing power grid assets, reducing or delaying the need for expensive infrastructure upgrades, while making utilities better prepared to meet the growing electricity demand fueled by the ongoing energy transition.
The sphere-shaped sensor-units, called Neurons by Heimdall Power, gather live data that allows the company’s advanced software to assess the actual transmission line capacity in real-time. This way, utilities can harness the increased capacity made available by Dynamic Line Ratings (DLR), moving on from the traditional static or seasonal line ratings that limit grid operators from utilizing power grids in a dynamic fashion.
The Neuron’s unique design and remarkable ability to squeeze more capacity out of the existing infrastructure has earned it recognition as a “Magic Ball” by top global media outlets like the Wall Street Journal, Forbes, and Yahoo. The sensor units can be installed in a matter of seconds on live power lines through a patented autonomous drone system, providing unrivaled scalability and efficiency while ensuring safety of workers. By combining them with their digital sibling, the AI-powered Virtual Neuron, Heimdall Power is the first to offer precise monitoring of overhead lines at system-wide scale.
“We have reached many key milestones in Heimdall Power during the past year, but this is the biggest yet and the timing is perfect. The U.S. government recently announced a goal to upgrade 100,000 miles of transmission lines in the next few years, and powered by this Series B round, we’ll do our fair share to fulfill that vision,” said Jørgen Festervoll, CEO of Heimdall Power. “This funding gives us fuel to grow internationally, as we continue to build our organization with the best people and industry experts in the world. It will also allow us to make further investments in our tech-development, taking scalability to the next level as we strengthen our position as the clear world-leader within Grid-Enhancing Technologies,” Festervoll concluded.
Heimdall Power is trusted by more than 40 utilities in 17 countries across Europe, Asia, and the U.S. The company recently caught the attention of the U.S. government after launching the largest grid optimization project in the United States with Minnesota’s Great River Energy, and was subsequently invited to the White House in Washington D.C. for a summit on Grid Modernization.
“Heimdall Power has built itself a unique position as an enabler for the ongoing energy transition with, fast-increasing electricity demand and queues of renewables waiting to get connected. As the owner of one of Poland’s four utilities, we have observed the growing challenges power grids around the world are facing” said Marek Garniewski, President of the Management Board at Orlen VC. “The ability of Heimdall’s solutions to increase grid capacity by 40% is not just impressive, it's transformative. Combined with the increasingly strong governmental interest and new mandates coming out of the U.S. and Europe we are happy to be part of this investment opportunity, supporting Heimdall Power in their ongoing international growth journey.”
Sharing in the excitement about the company’s future, Patrick Sandahl, Investment Director at Investinor, added: "As both an investor and board member, I've witnessed Heimdall Power's remarkable journey firsthand. Their technology has already started to reshape the entire energy sector. This funding round is a testament to the team's vision and execution, cementing Heimdall Power’s pivotal role in modernizing power grids globally."
About Heimdall Power
Heimdall Power is a technology company that specializes in power grid optimization, making the world's grids smarter, more capable and more sustainable. Heimdall Power’s technology is trusted by over 40 utilities in 17 countries, across Europe, Asia and in the United States, where it has successfully increased power grid capacity for companies like Swissgrid, Austrian Power Grid, TenneT and Great River Energy by as much as 40% on average. The company designs and develops smart software solutions and industrial devices in support of its mission to enable a swift, secure and affordable energy transition around the world. Heimdall Power was founded in 2016 with European headquarters in Oslo, Norway and US headquarters located in Charlotte, North Carolina.
About ORLEN Group
The ORLEN Group is an integrated multi-utility energy company listed in the prestigious global Fortune Global 500. It was the first company in the region to declare achieving total emission neutrality in 2050. Thanks to the recent acquisitions and mergers, it became one of the 150 largest companies in the world. The company operates on 10 home markets: Poland, Czech Republic, Germany, Lithuania, Slovakia, Hungary, Austria, Canada, Norway and Pakistan. By the end of this decade, ORLEN will invest over PLN 320 billion to implement strategic projects, of which approximately 40% will be allocated to green investments, including wind energy at sea and on land, photovoltaics, biogas and biomethane, biofuels, electromobility, green hydrogen and synthetic fuels.
About NRP Zero
NRP Zero is an Oslo-based industrial cleantech fund manager investing in late-stage venture companies accelerating the energy transition and optimizing resource efficiency with a positive impact beyond the Nordics. Through active engagement with companies’ management teams and stakeholders, we seek to amplify long-term returns while delivering positive and sustainable environmental outcomes. The investment team comprises of five professionals with longstanding experience in active ownership at the cross-section of industry, energy and finance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716656922/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom